- Home
- PYN vs DYAI Comparison
PYN vs DYAI Comparison
Compare PYN & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- DYAI
- Stock Information
- Founded
- PYN 2002
- DYAI 1979
- Country
- PYN United States
- DYAI United States
- Employees
- PYN N/A
- DYAI 6
- Industry
- PYN Investment Managers
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PYN Finance
- DYAI Health Care
- Exchange
- PYN Nasdaq
- DYAI Nasdaq
- Market Cap
- PYN 30.1M
- DYAI 28.3M
- IPO Year
- PYN N/A
- DYAI 2004
- Fundamental
- Price
- PYN $5.37
- DYAI $0.97
- Analyst Decision
- PYN
- DYAI Strong Buy
- Analyst Count
- PYN 0
- DYAI 1
- Target Price
- PYN N/A
- DYAI $6.00
- AVG Volume (30 Days)
- PYN 19.9K
- DYAI 61.9K
- Earning Date
- PYN 01-01-0001
- DYAI 08-12-2025
- Dividend Yield
- PYN 5.07%
- DYAI N/A
- EPS Growth
- PYN N/A
- DYAI N/A
- EPS
- PYN N/A
- DYAI N/A
- Revenue
- PYN N/A
- DYAI $3,554,344.00
- Revenue This Year
- PYN N/A
- DYAI $22.56
- Revenue Next Year
- PYN N/A
- DYAI $30.95
- P/E Ratio
- PYN N/A
- DYAI N/A
- Revenue Growth
- PYN N/A
- DYAI 57.59
- 52 Week Low
- PYN $4.84
- DYAI $0.91
- 52 Week High
- PYN $6.60
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- PYN 63.98
- DYAI 53.08
- Support Level
- PYN $5.25
- DYAI $0.91
- Resistance Level
- PYN $6.13
- DYAI $0.99
- Average True Range (ATR)
- PYN 0.10
- DYAI 0.06
- MACD
- PYN 0.02
- DYAI 0.01
- Stochastic Oscillator
- PYN 18.28
- DYAI 59.93
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.